Brought to you by 
Biovail acquires Fuisz Technologies
15 Mar 2001
Executive Summary
Biovail (drug delivery) acquired oral drug delivery company Fuisz Technologies for approximately $245.2mm--about 4 times its 1998 sales--in a two-stage transaction, consisting of about $75.6mm in cash, $78.6mm in stock, and $91mm in debt. Biovail valued Fuisz's approximately 22mm outstanding shares at $7.00 each, a (pr)41% premium to market average.
Deal Industry
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biovail acquires Fuisz Technologies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice